NasdaqCM - Delayed Quote USD

Tharimmune, Inc. (THAR)

1.5761
+0.0159
+(1.02%)
At close: June 4 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
12,633.1580
12,433.7920
9,455.2200
6,881.9380
3,208.0170
Operating Income
-12,633.1580
-12,433.7920
-9,455.2200
-6,881.9380
-3,208.0170
Net Non Operating Interest Income Expense
149.9950
236.2240
136.1260
-1,591.2440
-831.2770
Other Income Expense
--
--
--
--
1,832.6510
Pretax Income
-12,483.1630
-12,197.5680
-9,319.0940
-8,473.1820
-2,206.6430
Net Income Common Stockholders
-12,483.1630
-12,197.5680
-9,319.0940
-8,473.1820
-2,206.6430
Diluted NI Available to Com Stockholders
-12,483.1630
-12,197.5680
-9,319.0940
-8,473.1820
-2,206.6430
Basic EPS
-7.85
-9.41
-107.02
-280.80
-80.38
Diluted EPS
-7.85
-9.41
-107.02
-280.80
-80.38
Basic Average Shares
1,718.0480
1,296.2900
87.0790
30.1790
27.4540
Diluted Average Shares
1,718.0480
1,296.2900
87.0790
30.1790
27.4540
Total Operating Income as Reported
-12,633.1580
-12,433.7920
-9,455.2200
-6,881.9380
-3,208.0170
Total Expenses
12,633.1580
12,433.7920
9,455.2200
6,881.9380
3,208.0170
Net Income from Continuing & Discontinued Operation
-12,483.1630
-12,197.5680
-9,319.0940
-8,473.1820
-2,206.6430
Normalized Income
-12,483.1630
-12,197.5680
-9,319.0940
-8,473.1820
-2,206.6430
Interest Income
167.4500
249.9080
152.6310
0
--
Interest Expense
17.4550
13.6840
16.5050
1,591.2440
831.2770
Net Interest Income
149.9950
236.2240
136.1260
-1,591.2440
-831.2770
EBIT
-12,465.7080
-12,183.8840
-9,302.5890
-6,881.9380
-1,375.3660
EBITDA
-12,465.7080
-12,183.8840
-9,302.5890
-6,881.9380
-1,375.3660
Net Income from Continuing Operation Net Minority Interest
-12,483.1630
-12,197.5680
-9,319.0940
-8,473.1820
-2,206.6430
Total Unusual Items Excluding Goodwill
--
--
--
--
0
Total Unusual Items
--
--
--
--
0
Normalized EBITDA
-12,465.7080
-12,183.8840
-9,302.5890
-6,881.9380
-1,375.3660
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 1/12/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ARTL Artelo Biosciences, Inc.
1.1006
+2.86%
 
SNPX Synaptogenix, Inc.
2.6069
+0.07%
 
APTOF Aptose Biosciences Inc.
1.7600
+3.53%
 
ALEC Alector, Inc.
1.5500
+4.73%
 
IPHA Innate Pharma S.A.
2.1400
+0.47%
 
NERV Minerva Neurosciences, Inc.
1.8500
+5.41%
 
FENC Fennec Pharmaceuticals Inc.
7.68
-2.54%
 
ATNF 180 Life Sciences Corp.
1.0692
+5.84%
 
COEP Coeptis Therapeutics Holdings, Inc.
9.48
-0.68%
 
PHGE BiomX Inc.
0.5130
+2.40%